107220-28-0 Usage
Description
Cevimeline Hydrochloride Salt is a novel muscarinic M1 and M3 receptor agonist, characterized by its off-white solid appearance. It is primarily known for its role as a sialagogue, which means it stimulates the secretion of saliva.
Uses
Used in Pharmaceutical Industry:
Cevimeline Hydrochloride Salt is used as a therapeutic agent for the treatment of dry mouth (xerostomia) and other conditions related to reduced salivary gland function. Its agonistic action on muscarinic M1 and M3 receptors promotes increased saliva production, providing relief and improving the quality of life for patients suffering from these conditions.
Additionally, due to its muscarinic receptor agonist properties, Cevimeline Hydrochloride Salt may also have potential applications in other areas of medicine, such as the treatment of gastrointestinal disorders or cognitive impairments, although these uses would require further research and clinical validation.
Biological Activity
Selective M 1 receptor agonist. Induces atropine-sensitive contractions of isolated guinea pig ilea and trachea preparations (EC 50 values are 3.5 and 3 μ M respectively). Reverses AF64A-induced cognitive impairments in vivo .
Check Digit Verification of cas no
The CAS Registry Mumber 107220-28-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,7,2,2 and 0 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 107220-28:
(8*1)+(7*0)+(6*7)+(5*2)+(4*2)+(3*0)+(2*2)+(1*8)=80
80 % 10 = 0
So 107220-28-0 is a valid CAS Registry Number.
107220-28-0Relevant articles and documents
A new route to cevimeline
Pramanik, Chinmoy,Patil, Pradip,Kotharkar, Sandeep,Tripathy, Narendra K.,Gurjar, Mukund K.
, p. 3043 - 3045 (2013/06/27)
The present work demonstrates a new route for the synthesis of cevimeline in which safe and odorless thiourea is utilized as a thiolating reagent.
OPHTHALMIC PERCUTANEOUSLY ABSORBED PREPARATION CONTAINING MUSCARINIC RECEPTOR AGONIST
-
Page/Page column 11, (2008/06/13)
A percutaneous absorption type ophthalmic preparation comprising muscarinic receptor agonist is prepared, which can promote lacrimal fluid secretion by administration to the skin surface of the eyelid, and which causes fewer side effects such as miosis, thereby to provide a percutaneous absorption type ophthalmic preparation capable of maintaining a therapeutically effective concentration of a muscarinic receptor agonist for promoting lacrimal fluid secretion, which is associated with fewer side effects such as miosis, and a method of promoting lacrimal fluid secretion by administering a percutaneous absorption type ophthalmic preparation containing a muscarinic receptor agonist to the skin surface of the eyelid.